Multiple Sclerosis Drugs - Serbia

Serbia

In Serbia, the revenue in the Multiple Sclerosis Drugs market is projected to reach US$8.17m in 2024.
The market is expected to show an annual growth rate (CAGR 2024-2029) of 1.40%, resulting in a market volume of US$8.76m by 2029.
When compared globally, United States is expected to generate the highest revenue in this market, with US$11,770.00m in 2024.
Serbia's multiple sclerosis drugs market is witnessing a surge in research and development activities, attracting global pharmaceutical companies to invest in the country.

Key regions: France, India, United Kingdom, South Korea, Japan

Market

Region

Region comparison

Currency

Analyst Opinion

The Multiple Sclerosis Drugs market in Serbia has been experiencing steady growth in recent years.

Customer preferences: Serbian customers have been showing a growing interest in Multiple Sclerosis Drugs due to the increasing awareness of the disease and the availability of effective treatments. Patients are seeking drugs that can help manage the symptoms of the disease and improve their quality of life. They are also looking for affordable options that can be accessed easily.

Trends in the market: The Multiple Sclerosis Drugs market in Serbia is experiencing a trend towards the use of newer, more effective drugs. This is due to the increasing availability of these drugs in the market and the growing awareness among healthcare professionals of their benefits. Additionally, there is a trend towards the use of drugs that can be administered orally, as they are more convenient for patients.

Local special circumstances: Serbia has a relatively high incidence of Multiple Sclerosis compared to other countries in the region. This has led to a growing demand for drugs that can help manage the symptoms of the disease. Additionally, the Serbian government has been taking steps to improve the healthcare system, which has led to an increase in the availability of drugs in the market.

Underlying macroeconomic factors: Serbia has been experiencing steady economic growth in recent years, which has led to an increase in disposable income and a growing middle class. This has resulted in a higher demand for healthcare services, including drugs for the treatment of Multiple Sclerosis. Additionally, the Serbian government has been implementing policies to improve access to healthcare services, which has led to an increase in the availability of drugs in the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.